KG
LFCR icon

Killen Group’s Lifecore Biomedical LFCR Stock Holding History

Killen Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$5.39M Sell
513,169
-342,945
-40% -$3.77M 0.62% 56
2015
Q4 		$10.1M Sell
856,114
-164,239
-16% -$2.02M 1.05% 38
2015
Q3 		$11.9M Sell
1,020,353
-102,104
-9% -$1.35M 1.11% 32
2015
Q2 		$16.2M Sell
1,122,457
-67,306
-6% -$971K 1.23% 28
2015
Q1 		$16.6M Sell
1,189,763
-100,084
-8% -$1.38M 1.19% 34
2014
Q4 		$17.8M Sell
1,289,847
-54,363
-4% -$702K 1.16% 37
2014
Q3 		$16.5M Buy
1,344,210
+29,650
+2% +$370K 0.92% 48
2014
Q2 		$16.4M Buy
1,314,560
+11,575
+0.9% +$136K 0.85% 53
2014
Q1 		$14.5M Buy
1,302,985
+20,625
+2% +$226K 0.79% 65
2013
Q4 		$15.5M Buy
1,282,360
+1,185
+0.1% +$14.2K 0.89% 59
2013
Q3 		$15.6M Sell
1,281,175
-26,852
-2% -$375K 0.93% 49
2013
Q2 		$17.3M Buy
+1,308,027
New +$18.1M 1.23% 22

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Killen Group's LFCR Position: Q1 2016 in Review

Killen Group reduced its Lifecore Biomedical (LFCR) stake by 40% in Q1 2016, selling an estimated $3.77M and leaving 513,169 shares worth $5.39M. The position accounts for 0.62% of the portfolio, ranked #56.

Killen Group first reported a position in LFCR in Q2 2013 and has held it in 12 quarters since. The position peaked at $17.8M in Q4 2014. 96 funds tracked by Wall St. Rank hold LFCR as of Q1 2016.

  • Killen Group held 513,169 shares of Lifecore Biomedical worth $5.39M as of Q1 2016.
  • Killen Group sold 342,945 Lifecore Biomedical shares in Q1 2016, an estimated $3.77M.
  • Lifecore Biomedical made up 0.62% of Killen Group's portfolio in Q1 2016, its #56 holding.
  • Killen Group first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 12 quarters since.
  • Killen Group's Lifecore Biomedical position peaked at $17.8M in Q4 2014.
  • 96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2016.

Based on Killen Group's 13F filing for Q1 2016, filed 27 Apr 2016.